Two privately-held biotechs have merged to tackle recurrent C. difficile infections. Source: BioSpace

If J&J's going to keep rewarding investors, it's going to need these top drugs to continue racking up sales. Source: BioSpace

In order to meet growing demand for insulin, pharma giant Eli Lilly said it will invest $72M to expand insulin manufacturing capabilities at one of its Indianapolis facilities. Source: BioSpace

Celgene is scrapping a late-stage Crohn's disease drug it acquired in a $710M deal three years ago following an interim data analysis. Source: BioSpace

The company was among dozens of firms worldwide hit in the June 27 attack. Source: BioSpace

CAR-T therapy is the big thing right now, with this week's approval of Gilead Yescarta and the recent approval of Novartis' Kymriah. Source: BioSpace

Universal Cells will get $9 million upfront and is eligible to regulatory milestones payments of up to $115 million, as well as royalties. Source: BioSpace

DURECT's Posimir (SABER - Bupivacaine) for post-surgical pain failed its Phase III clinical trial. Source: BioSpace

Allergan is a good example of how many mergers and acquisitions over a very short period of time created a large, international company. Source: BioSpace

Analysts with SunTrust Robinson Humphrey recently published a research report that looked at a number of large-cap pharma companies. Source: BioSpace